Search Results - "Galvez, Carlos Cabrera"

Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape by Simard, Manon A, Cabrera-Galvez, Carlos, Viteri, Santiago, Geist, Felix, Reischmann, Nadine, Zühlsdorf, Michael, Karachaliou, Niki

“…•Tepotinib downstages NSCLC from IIIB to IA1 in a patient with a METex14 skipping alteration.•GeoMx spatial analysis reveals increased immune cell diversity…”
Get full text

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer by Viteri, Santiago, Cabrera-Gálvez, Carlos, Rosell, Rafael

Get full text

RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients by Aguado, Cristina, Giménez-Capitán, Ana, Román, Ruth, Rodríguez, Sonia, Jordana-Ariza, Núria, Aguilar, Andrés, Cabrera-Gálvez, Carlos, Rivas-Corredor, Carlos, Lianes, Pilar, Viteri, Santiago, Moya, Irene, Molina-Vila, Miguel A

“…The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon…”
Get full text

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx) by Le, Xiuning, Paz-Ares, Luis, Van Meerbeeck, Jan, Viteri Ramirez, Santiago, Cabrera Galvez, Carlos, Vicente Baz, David, Kim, Young-Chul, Kang, Jin-Hyoung, Stroh, Christopher, Juraeva, Dilafruz, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Paik, Paul K.

“…9121 Background: Tepotinib, a potent, highly selective, oral, MET inhibitor, showed meaningful activity in patients (pts) with NSCLC with high-level METamp by…”
Get full text

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification ( MET amp) by Le, Xiuning, Paz-Ares, Luis G., Van Meerbeeck, Jan, Viteri, Santiago, Cabrera Galvez, Carlos, Vicente Baz, David, Kim, Young-Chul, Kang, Jin-Hyoung, Schumacher, Karl-Maria, Karachaliou, Niki, Adrian, Svenja, Bruns, Rolf, Paik, Paul K.

“…Abstract only 9021 Background: METamp is an oncogenic driver occurring in 1–5% of NSCLCs that confers a poor prognosis and lacks approved targeted therapies…”
Get full text

T-cell infiltration in matched samples from malignant pleural mesothelioma (MPM) during evolution of disease by Cedres Perez, Susana, Serna, Garazi, Assaf Pastrana, Juan David, Iranzo, Patricia, Callejo, Ana, Pardo, Nuria, Navarro, Alejandro, Martinez-Marti, Alex, Cabrera Galvez, Carlos, Gonzalez-Medina, Alberto, Fasani, Roberta, Guardia, Xavier, Gonzalo, Javier, Carbonell, Caterina, Frigola, Joan, Amat, Ramon, Vivancos, Ana, Nuciforo, Paolo, Felip, Enriqueta

“…e20595 Background: MPM is an aggressive cancer associated with asbestos exposure. Chemotherapy has been a mainstay of therapy and recently immunotherapy has…”
Get full text

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B by Le, Xiuning, Paz-Ares, Luis G, Van Meerbeeck, Jan, Viteri, Santiago, Galvez, Carlos Cabrera, Smit, Egbert F, Garassino, Marina, Veillon, Remi, Baz, David Vicente, Pradera, Jose Fuentes, Sereno, María, Kozuki, Toshiyuki, Kim, Young-Chul, Yoo, Seung Soo, Han, Ji-Youn, Kang, Jin-Hyoung, Son, Choon-Hee, Choi, Yoon Ji, Stroh, Christopher, Juraeva, Dilafruz, Vioix, Helene, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Paik, Paul K

“…High-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates…”
Get full text

Abstract 2606: A nCounter-Based mRNA signature in plasma associates with localized non-small cell lung cancer by Capitán, Ana Giménez, Bracht, Jillian, Potie, Nicolas, González-Cao, María, Viteri, Santiago, Martínez-Bueno, Alejandro, Cabrera-Gálvez, Carlos, Rubinstein, Pablo, Mayo-de-las-Casas, Clara, Valarezo, Joselyn, Huang, Chung-Ying, Pedraz, Carlos, Boykind, Richard, Warren, Sarah, Rosell, Rafael, Molina-Vilaa, Miguel Ángel, Aguilar-Hernández, Andrés

“…Background: 80% of non-small cell lung cancer (NSCLC) cases are diagnosed at stages IIIB-IV and have a dismal prognosis with a median life expectancy that does…”
Get full text